Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Lifecore Biomedical, Inc. Common Stock

LFCR

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Last trade $6.40
Day change -$0.015 (-0.23%)
Day range $6.40 – $6.42
Volume 109,129
Market cap $243M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$243.36M
Price / earnings
—
Price / book
-10.92×
Price / sales
2.14×
EV / sales
1.98×
EV / EBITDA
-60.13×

Profitability

Earnings per share
-$1.98
Return on assets
-32.85%
Return on equity
336.68%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.25×
Current ratio
3.84×
Quick ratio
2.59×
Cash ratio
1.05×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
—

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LFCR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q2 FY2026 Sep 30, 2025Q3 FY2025 Sep 30, 2025Q1 FY2025 May 25, 2025Q4 FY2025 Feb 23, 2025Q2 FY2025 Aug 25, 2024
Revenue$25.32M$34.17M$23.19M$31.11M$31.11M$36.44M$35.15M$24.71M
Cost of revenue$18.5M$22.09M$18.73M$23.32M$23.32M$22.46M$25.31M$19.32M
Gross profit$6.83M$12.08M$4.46M$7.79M$7.79M$13.98M$9.85M$5.39M
Selling, general and administrative$6.3M$7.97M$7.92M$8.9M$8.9M$8.98M$9.98M$14.79M
Research and development$1.42M$1.54M$1.22M$1.96M$1.96M$2.1M$2.05M$2.19M
Total operating expenses$7.72M$9.51M$9.13M$10.86M$10.86M$8.56M$12.02M$16.97M
Operating income-$894K$2.57M-$4.67M-$3.07M-$3.07M$5.42M-$2.18M-$11.58M
Interest expense-$8.1M-$7.75M-$7.35M-$6.38M-$6.38M-$5.73M-$5.59M-$5.38M
Income before taxes-$40.03M-$6.13M-$14.94M-$9.66M-$9.66M-$1.11M-$14.78M-$16.26M
Income taxes$51K$23K$43K$333K$333K$33K-$8K-$25K
Net income-$40.08M-$6.16M-$14.98M-$9.99M-$9.99M-$1.15M-$14.77M-$16.23M
Net income attributable to common shareholders-$41.03M-$7.13M-$15.93M-$10.91M-$10.91M-$2.05M-$15.65M-$16.23M
EBITDA-$894K$2.57M-$2.36M-$1.09M-$3.07M$2.9M-$102K-$9.59M
Basic earnings per share-$1.08-$0.19-$0.43-$0.29-$0.29-$0.06-$0.42-$0.53
Diluted earnings per share-$1.08-$0.19-$0.43-$0.29-$0.29-$0.06-$0.42-$0.53

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Halper Sadeh LLC is Investigating Whether MG, LFCR, MGLD are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether MISTRAS Group's $20.35/share sale to H.I.G. Capital, Lifecore Biomedical's $6.28/share sale to Webster Equity Partners, and Marygold Companies' $2.00/share sale to Madison Dearborn Partners represent fair deals for shareholders. The firm may seek increased consideration, additional disclosures, and other relief on behalf of shareholders.

GlobeNewswire Inc.

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCR

A proposed class action settlement of $3,750,000 has been reached on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020, and March 19, 2024. The settlement requires court approval at a hearing scheduled for July 28, 2026. Class members must submit claim forms by July 7, 2026, to be eligible for distribution from the settlement fund.

GlobeNewswire Inc.

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical announced it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. This is the company's third commercial site transfer since October 2025. The product is expected to generate commercial revenue within 24 months and contribute to Lifecore's targeted 2029 revenue CAGR of 12%. The agreement demonstrates successful execution of the company's strategy to secure lower-risk, late-stage programs with faster paths to commercial revenue.

GlobeNewswire Inc.

Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP announced investigations into potential securities law violations by Green Dot Corporation, Lifecore Biomedical, and Horizon Technology Finance on behalf of affected investors. Green Dot's stock declined approximately 7% following the company's announcement of delayed financial results for Q4 and full year 2025.

GlobeNewswire Inc.

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP announced investigations into three companies on March 16, 2026. Lifecore Biomedical issued disappointing 2026 revenue guidance of $120-125 million versus $141.4 million in 2025, citing customer loss and product launch delays, resulting in an 18% stock decline. The firm is also investigating Horizon Technology Finance and G-III Apparel Group for potential federal securities law violations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.